I'm still in. Think the surest bet we have going for us is the SCM case. $30M would do wonders for this stock and it has nothing to do with validity in the patents.....the case is all about a contract breach that SCM is in violation of. Add that into a Celgene payment and delayed MMR PRo payments and i really think this could be a very successful year regardless of what else happens.